other material
confidence high
sentiment positive
materiality 0.70
Cogent Biosciences reports positive Phase 3 PEAK lead-in data for bezuclastinib in GIST
Cogent Biosciences, Inc.
- 39 patients treated; 55% disease control rate across efficacy-evaluable patients in Part 1.
- In 2nd-line Part 1a: 100% disease control rate and 17% overall response rate.
- Safety profile well-tolerated; 2 discontinuations due to AEs; low Grade ≥3 events.
- Part 2 enrollment ongoing (target ~388 2nd-line GIST patients); SUMMIT/APEX data expected H2 2023.